fda glp-1 enforcement news today Pipeline Update: November 2025 - Prime Therapeutics Harnessing GLP-1 Receptor Agonists for

TRICARE policy has never approved coverage for GLP-1 drugs simply to lose weight or for cosmetic purposes

These include extracts like white kidney bean (inhibits carb-digesting enzymes) or chitosan (binds dietary fat to limit absorption)

Side effects, particularly gastrointestinal symptoms, can be more disruptive in individuals who are not accustomed to chronic medication use

The hospital pharmacies segment dominated the market with a 46.80% share in 2025, owing to the high volume of diabetes and obesity prescriptions initiated within hospital and specialty care settings

We never recommend stopping a medication without coordination with your prescribing doctor, as this could affect your diabetes control

The preferred site for most researchers due to consistent absorption and easy access